223 related articles for article (PubMed ID: 32515921)
21. The mitosis-specific marker phosphohistone-H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumours: an outcome-based study.
Chow KL; Tse KY; Cheung CL; Wong KW; Cheung AN; Wong RW; Chan AN; Yuen NW; Ngan HY; Ip PP
Histopathology; 2017 Apr; 70(5):746-755. PubMed ID: 27864989
[TBL] [Abstract][Full Text] [Related]
22. Differential Immunoreactivity of p16 in leiomyosarcomas and leiomyoma variants.
Gannon BR; Manduch M; Childs TJ
Int J Gynecol Pathol; 2008 Jan; 27(1):68-73. PubMed ID: 18156978
[TBL] [Abstract][Full Text] [Related]
23. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
24. [Practical diagnostic aspects of uterine leiomyosarcoma in the context of the 2020 WHO classification].
Horn LC; Hiller GGR; Mayr D; Schmoeckel E; Höhn AK
Pathologe; 2022 May; 43(3):196-201. PubMed ID: 35412039
[TBL] [Abstract][Full Text] [Related]
25. p53, p16 and ki67 as immunohistochemical prognostic markers in uterine smooth muscle tumors of uncertain malignant potential (STUMP).
Travaglino A; Raffone A; Gencarelli A; Neola D; Oliviero DA; Alfano R; Campanino MR; Cariati F; Zullo F; Mollo A; Insabato L
Pathol Res Pract; 2021 Oct; 226():153592. PubMed ID: 34481212
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical analysis in the diagnosis of uterine myometrial smooth muscle tumors.
Stănescu AD; Nistor E; Sajin M; Stepan AE
Rom J Morphol Embryol; 2014; 55(3 Suppl):1129-36. PubMed ID: 25607395
[TBL] [Abstract][Full Text] [Related]
27. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases.
Ip PP; Cheung AN; Clement PB
Am J Surg Pathol; 2009 Jul; 33(7):992-1005. PubMed ID: 19417585
[TBL] [Abstract][Full Text] [Related]
28. Leiomyoma and Leiomyosarcoma (Primary and Metastatic) of the Oral and Maxillofacial Region: A Clinicopathological and Immunohistochemical Study of 27 Cases.
de Araújo GR; Costa SFDS; Mesquita RA; Gomez RS; Dos Santos JN; Pontes HAR; de Andrade BAB; Romañach MJ; Agostini M; Vargas PA; de Cáceres CVBL; Santos-Silva AR; Ribeiro ACP; Brandão TB; Tomasi RA; Ferreyra RS; de Almeida OP; Fonseca FP
Head Neck Pathol; 2022 Mar; 16(1):294-303. PubMed ID: 34106410
[TBL] [Abstract][Full Text] [Related]
29. Fascin expression in uterine smooth muscle tumors.
Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B
Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633
[TBL] [Abstract][Full Text] [Related]
30. Potential diagnostic biomarkers: differential expression of LMP2/β1i and cyclin B1 in human uterine leiomyosarcoma.
Hayashi T; Horiuchi A; Sano K; Hiraoka N; Ichimura T; Sudo T; Ishiko O; Yaegashi N; Aburatani H; Konishi I
Tumori; 2014; 100(4):99e-106e. PubMed ID: 25296613
[TBL] [Abstract][Full Text] [Related]
31. Use of histone deacetylase 8 (HDAC8), a new marker of smooth muscle differentiation, in the classification of mesenchymal tumors of the uterus.
de Leval L; Waltregny D; Boniver J; Young RH; Castronovo V; Oliva E
Am J Surg Pathol; 2006 Mar; 30(3):319-27. PubMed ID: 16538051
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors.
Hewedi IH; Radwan NA; Shash LS
Diagn Pathol; 2012 Jan; 7():1. PubMed ID: 22217299
[TBL] [Abstract][Full Text] [Related]
33. The evaluation of the caveolin-1 and AT-rich interactive domain 1 alpha expressions in uterine smooth muscle tumors.
Ayaz D; Diniz G; Kahraman DS; Sayhan S; Uncel M; Karadeniz T; Sanci M
Indian J Pathol Microbiol; 2016; 59(3):301-4. PubMed ID: 27510664
[TBL] [Abstract][Full Text] [Related]
34. TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma.
Baiocchi G; Poliseli FL; De Brot L; Mantoan H; Schiavon BN; Faloppa CC; Vassallo J; Soares FA; Cunha IW
J Clin Pathol; 2016 Oct; 69(10):884-9. PubMed ID: 26994023
[TBL] [Abstract][Full Text] [Related]
35. The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors.
Atkins KA; Arronte N; Darus CJ; Rice LW
Am J Surg Pathol; 2008 Jan; 32(1):98-102. PubMed ID: 18162776
[TBL] [Abstract][Full Text] [Related]
36. Uterine leiomyosarcoma arising in leiomyoma: clinicopathological study of four cases and literature review.
Yanai H; Wani Y; Notohara K; Takada S; Yoshino T
Pathol Int; 2010 Jul; 60(7):506-9. PubMed ID: 20594271
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical Profile of Uterine Leiomyoma With Bizarre Nuclei; Comparison With Conventional Leiomyoma, Smooth Muscle Tumors of Uncertain Malignant Potential and Leiomyosarcoma.
Dastranj Tabrizi A; Ghojazadeh M; Thagizadeh Anvar H; Vahedi A; Naji S; Mostafidi E; Berenjian S
Adv Pharm Bull; 2015 Dec; 5(Suppl 1):683-7. PubMed ID: 26793616
[TBL] [Abstract][Full Text] [Related]
38. Value of counting positive PHH3 cells in the diagnosis of uterine smooth muscle tumors.
Pang SJ; Li CC; Shen Y; Liu YZ; Shi YQ; Liu YX
Int J Clin Exp Pathol; 2015; 8(5):4418-26. PubMed ID: 26191133
[TBL] [Abstract][Full Text] [Related]
39. Digital Quantification of Ki-67 and PHH3 in the Classification of Uterine Smooth Muscle Tumors.
Cao CD; Rico-Castillo J; De Cotiis D; Richard SD; Rosenblum NG; Chan JSY
Int J Gynecol Pathol; 2021 Nov; 40(6):549-555. PubMed ID: 33323861
[TBL] [Abstract][Full Text] [Related]
40. Primary and secondary leiomyosarcoma of the oral and perioral region--clinicopathological and immunohistochemical analysis of a rare entity with a review of the literature.
Schütz A; Smeets R; Driemel O; Hakim SG; Kosmehl H; Hanken H; Kolk A
J Oral Maxillofac Surg; 2013 Jun; 71(6):1132-42. PubMed ID: 23434173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
